Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. Issue 6 (August 2019)

• Record Type: Journal Article
• Authors: Jayanthan, Aarthi; Hofmann, Bradley; Meier-Stephenson, Vanessa; Perinpanayagam, Maneka; Dunn, Sandra E.; Boklan, Jessica; Trippett, Tanya M.; Truong, Tony H.; Narendran, Aru
• Is Part Of: Journal of pediatric hematology/oncology. Volume 41:Issue 6(2019)
• Publication Date: 2019-08
• Subjects: polo-like kinases -- pediatric leukemia -- Aurora kinases -- targeted therapeutics; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001416
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Background: Recent studies have shown that cell cycle events are tightly controlled by complex and shared activities of a select group of kinases. Among these, polo-like kinases (Plks) are regulatory mitotic proteins that are overexpressed in several types of cancer and are associated with poor prognosis. Materials and Methods: We have evaluated, in preclinical in vitro studies, the activity of a panel of Plk inhibitors against cell lines derived from refractory pediatric leukemia, as well as primary leukemia cells, in culture. Through in vitro growth inhibition studies, Western blot analysis for the expression and activation of key regulators of cell growth and survival and gene silencing studies, we specifically examined the ability of these agents to induce cytotoxicity through the activation of apoptosis and their capacity to interact and modulate the expression and phosphorylation of Aurora kinases. Results: Our findings show that the various Plk-1 inhibitors in development show potential utility for the treatment of pediatric leukemia and exhibit a wide range of phosphorylation and target modulatory capabilities. Finally, we provide evidence for a complex interregulatory relationship between Plk-1 and Aurora kinases enabling the identification of synergy and biologic correlates of drug combinations targeting the 2 distinct enzyme systems. Discussion: This information provide the rationale for the evaluation of Plk-1 as an effective target for therapeutics in refractory pediatric leukemia and indicate compensatory activities between Plk-1 and Aurora kinases, providing insight into some of the complex mechanisms involved in the process of cell division. Abstract : Supplemental Digital Content is available in the text.